Avacta Group (LON:AVCT – Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported GBX (9.27) EPS for the quarter, Digital Look Earnings reports. The company had revenue of GBX 11 million for the quarter. Avacta Group had a negative return on equity of 361.23% and a negative net margin of 30,398.21%.
Avacta Group Price Performance
Shares of AVCT opened at GBX 80.69 on Wednesday. Avacta Group has a 12-month low of GBX 26 and a 12-month high of GBX 92. The business’s fifty day moving average is GBX 72.88 and its 200 day moving average is GBX 67.95. The company has a quick ratio of 4.96, a current ratio of 0.79 and a debt-to-equity ratio of 14,168.75. The stock has a market cap of £365.91 million, a P/E ratio of -4.60 and a beta of 1.12.
About Avacta Group
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.
Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).
Read More
- Five stocks we like better than Avacta Group
- Vertical Aerospace: Pre-Flight Checks Point to a Breakout
- Palo Alto Networks Up 70%: Can the Rally Last Into June?
- Block’s Pivot to Profits and AI Is Turning Heads
- HIVE Weaponizes Power for an AI Pivot
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
